Penn Capital Management Co. Inc. reduced its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 11.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 889,636 shares of the medical instruments supplier’s stock after selling 119,635 shares during the period. Penn Capital Management Co. Inc.’s holdings in OraSure Technologies were worth $10,672,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Everence Capital Management Inc. bought a new position in OraSure Technologies in the 1st quarter valued at $156,000. Texas Permanent School Fund grew its position in OraSure Technologies by 4.5% in the 1st quarter. Texas Permanent School Fund now owns 41,868 shares of the medical instruments supplier’s stock valued at $467,000 after acquiring an additional 1,787 shares during the last quarter. Comerica Bank grew its position in OraSure Technologies by 3.2% in the 1st quarter. Comerica Bank now owns 60,719 shares of the medical instruments supplier’s stock valued at $632,000 after acquiring an additional 1,896 shares during the last quarter. Sicart Associates LLC lifted its holdings in shares of OraSure Technologies by 6.3% in the 1st quarter. Sicart Associates LLC now owns 452,349 shares of the medical instruments supplier’s stock worth $5,044,000 after buying an additional 26,800 shares during the period. Finally, Parallel Advisors LLC purchased a new stake in shares of OraSure Technologies in the 1st quarter worth $33,000. 88.67% of the stock is currently owned by hedge funds and other institutional investors.

Shares of OSUR stock traded up $0.44 during mid-day trading on Wednesday, hitting $9.18. The stock had a trading volume of 4,035 shares, compared to its average volume of 1,072,606. OraSure Technologies, Inc. has a 12-month low of $8.27 and a 12-month high of $17.97. The stock has a market capitalization of $528.67 million, a price-to-earnings ratio of 18.40, a P/E/G ratio of 2.96 and a beta of 1.16. The company has a current ratio of 7.52, a quick ratio of 6.56 and a debt-to-equity ratio of 0.02.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The business had revenue of $30.12 million during the quarter, compared to analysts’ expectations of $29.66 million. During the same period in the prior year, the business earned $0.07 EPS. The business’s revenue for the quarter was down 28.3% compared to the same quarter last year. Research analysts predict that OraSure Technologies, Inc. will post 0.23 EPS for the current fiscal year.

Several equities research analysts have weighed in on the company. Zacks Investment Research cut OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub cut OraSure Technologies from a “sell” rating to a “strong sell” rating in a report on Thursday, April 18th. Canaccord Genuity cut OraSure Technologies from a “buy” rating to a “hold” rating and set a $10.00 target price for the company. in a report on Thursday, May 9th. Finally, ValuEngine cut OraSure Technologies from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $10.00.

In related news, CFO Roberto Cuca acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average cost of $9.03 per share, for a total transaction of $90,300.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stephen S. Phd Tang sold 16,667 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $11.10, for a total value of $185,003.70. Following the sale, the chief executive officer now owns 135,627 shares of the company’s stock, valued at $1,505,459.70. The disclosure for this sale can be found here. Insiders acquired a total of 21,000 shares of company stock valued at $184,360 over the last quarter. Company insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Penn Capital Management Co. Inc. Has $10.67 Million Stake in OraSure Technologies, Inc. (OSUR)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/05/15/penn-capital-management-co-inc-has-10-67-million-stake-in-orasure-technologies-inc-osur.html.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.